Zenith Health Care reported a net profit of ₹0.51 lakh for the financial year ended March 31, 2026, a decline from ₹6.70 lakh in the previous year. Revenue from operations for FY26 stood at ₹1,052.22 lakh, compared to ₹1,132.97 lakh in FY25. The Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026, during a meeting held on May 29, 2026.

The company’s performance for the fourth quarter (Q4FY26) showed a net loss of ₹34.20 lakh, contrasting with a net profit of ₹10.97 lakh in the same period of the previous year. Revenue for Q4FY26 was ₹262.15 lakh, down from ₹342.53 lakh in Q4FY25. The Statutory Auditors, M/s. Doshi Doshi & Co., issued an audit report with an unmodified opinion on the standalone financial results.

Re-appointment of Joint Managing Director

The Board approved the re-appointment of Mr. Akshit Mahendra Raycha as Joint Managing Director for a further period of three years, effective from May 29, 2026, to April 28, 2029. The Nomination and Remuneration Committee recommended the appointment, which is subject to shareholder approval via a special resolution at the ensuing Annual General Meeting. The company will seek this approval within 90 days as per SEBI (LODR) regulations.

Mr. Raycha’s remuneration is set at up to ₹2,00,000 per month, totaling ₹24,00,000 per annum, reflecting an annual increase of ₹9,00,000. He is the son of Mahendra C. Raycha, the Chairman & Managing Director, and holds directorships in Zenith Lifecare Private Limited, Zenith Medicine Private Limited, and Achyut Healthcare Limited.

Internal Auditor Appointment

The Board appointed Mr. Tanaykumar Mohta as the Internal Auditor for FY27. The appointment is for a term of 12 months covering the financial year 2026-27. Mr. Mohta is a Chartered Accountant with membership number 164122 and firm registration number 140845W, possessing expertise in direct and indirect taxation, internal audits, and financial management.

Other Board Decisions

The Board approved the related party transactions entered into during the half-year ended March 31, 2026, and authorized the Managing Director to fix the record date and other details for the upcoming Annual General Meeting.

Financial Summary for FY26

Zenith Healthcare Limited has formally declared to the Bombay Stock Exchange that it does not qualify as a 'Large Corporate' under SEBI regulations for the financial year ended March 31, 2026. The pharmaceutical company submitted its compliance declaration on April 11, 2026, confirming non-applicability of specific disclosure requirements.

SEBI Compliance Declaration

The company's declaration pertains to SEBI Circular SEBI/HO/DDHS/CIR/P/144 dated November 26, 2018, which governs the raising of funds through debt securities by large corporate entities. Zenith Healthcare Limited confirmed that these provisions do not apply to its operations as it does not meet the criteria for classification as a 'Large Corporate' under the specified framework.

Financial Position Details

The company provided key financial metrics to support its non-applicability status:

Corporate Authorization

The declaration was formally authorized by three key executives of Zenith Healthcare Limited:

• Mahendra C. Raycha - Chairman & Managing Director (DIN: 00577647)
• Mihir S. Shah - Company Secretary & Compliance Officer (Membership No: A41922)
• Prashant Gupta - Chief Financial Officer

All three officials digitally signed the compliance documents on April 11, 2026, ensuring proper corporate governance and regulatory adherence.

Regulatory Framework Context

The SEBI circular in question establishes specific criteria for identifying large corporate entities and mandates certain disclosure requirements for fund raising through debt securities. Companies that do not meet the threshold criteria must submit formal declarations confirming their non-applicability status to maintain compliance with exchange listing requirements.

Zenith Healthcare Limited's proactive submission of this declaration demonstrates its commitment to maintaining transparent regulatory compliance and ensuring accurate classification under current SEBI frameworks for the financial year 2026.